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Abstract
Background: HIV-related immune-suppression increases the risk of malaria (infection, disease
and treatment failure) and probably the circulating parasite biomass, favoring the emergence of
drug resistance parasites.
Methods: The additional malaria parasite biomass related to HIV-1 co-infection in sub-Saharan
Africa was estimated by a mathematical model. Parasite biomass was computed as the incidence
rate of clinical malaria episodes multiplied by the number of parasites circulating in the peripheral
blood of patients at the time symptoms appear. A mathematical model estimated the influence of
HIV-1 infection on parasite density in clinical malaria by country and by age group, malaria
transmission intensity and urban/rural area. In a multivariate sensitivity analysis, 95% confidence
intervals (CIs) were calculated using the Monte Carlo simulation.
Results: The model shows that in 2005 HIV-1 increased the overall malaria parasite biomass by
18.0% (95%CI: 11.6–26.9). The largest relative increase (134.9–243.9%) was found in southern
Africa where HIV-1 prevalence is the highest and malaria transmission unstable. The largest
absolute increase was found in Zambia, Malawi, the Central African Republic and Mozambique,
where both malaria and HIV are highly endemic. A univariate sensitivity analysis shows that
estimates are sensitive to the magnitude of the impact of HIV-1 infection on the malaria incidence
rates and associated parasite densities.
Conclusion: The HIV-1 epidemic by increasing the malaria parasite biomass in sub-Saharan Africa
may also increase the emergence of antimalarial drug resistance, potentially affecting the health of
the whole population in countries endemic for both HIV-1 and malaria.
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Since the 1980s, the epidemiological overlap of HIV-1/
AIDS and malaria in tropical regions, and particularly in
Eastern and Southern Africa, has been cause for concern as
even a small interaction between the two diseases may be
of great public health importance [1-4]. HIV-1 and
malaria coexist in regions where the health surveillance
systems are poorly performing so that the magnitude of
any interaction is difficult to determine. Nevertheless, the
evidence of such interaction has recently grown and is still
increasing. The incidence of symptomatic malaria epi-
sodes, severe or uncomplicated, and the corresponding
parasite density is higher in HIV-1 infected individuals
with low CD4 count [5].
It has been recently stated that, in Sub-Saharan Africa, the
direct impact of HIV-1 infection on malaria morbidity
and mortality is limited as the two diseases do not have
the same geographical distribution and affect different age
groups [6]. However, a model assessing the impact of
HIV-1 on malaria in sub-Saharan Africa, estimated that in
areas of unstable malaria transmission, such as southern
Africa, the HIV-1 epidemic contributed to the increase of
malaria observed in the 1990s. Moreover, a recent mathe-
matical model indicated a significant role for the dual
infection in fueling the spread of both diseases in sub-
Saharan Africa [7]. Besides a direct effect, HIV-1 infection
may indirectly influence the malaria burden by increasing
the malaria parasite biomass and consequently the prob-
ability of drug resistant parasites emerging. Antimalarial
drug resistance, particularly for Plasmodium falciparum, is
considered a major contributor to the global resurgence of
malaria observed over the last three decades [8] and one
of the greatest obstacles for an effective malaria control
[9]. The basis of resistance lies in one or several genetic
mutations in the parasite genome. Malaria parasites with
such mutations when in contact with a given drug survive
the treatment and eventually spread. Assuming that the
occurrence of a de novo resistance mutation is evenly dis-
tributed among all parasites, a larger parasite biomass
would increase the probability of new resistant strains
emerging. Therefore, the additional malaria parasite bio-
mass related to HIV-1 infection was estimated by review-
ing the available literature on the impact of HIV-1
infection on malaria morbidity (incidence of clinical cases
and parasite density) at individual level, and HIV-1 prev-
alence and malaria transmission intensity data at country
level. The results of this analysis and the possible conse-
quences of HIV-1 on the emergence of antimalarial drug
resistance are reported and discussed below.
Methods
Definition of endemicity
The MARA ("Mapping Malaria Risk in Africa") climate
suitability index was used for determining the country
endemicity, i.e. high ≥ 0.75 and low <0.75 [10]. However,
Botswana, Namibia, South Africa, Swaziland, and Zimba-
bwe, because of their successful vector control pro-
gramme, were not classified according to this criterion
and despite a climate suitability index >0.75 were consid-
ered as low rather than high transmission areas [10].
Malaria incidence and parasite density without HIV-1 
infection
Incidence rates of symptomatic malaria (uncomplicated
and severe) by transmission intensity and age group were
collected from the available literature [6]. In high
endemic rural areas the average incidence was estimated
at 1.4 malaria episodes/person-year (py) among children
<5 years of age, 0.59/py in the 5–14 year old and 0.11/py
in adults (≥ 15 year old)[10]. In low endemic rural areas,
incidence was estimated at 0.18/py in children <15 years
old and 0.09/py in those aged 15 years and above (Table
1). In high endemic urban areas, the malaria incidence
was estimated to be similar to that in low endemic rural
areas while in low endemic urban areas, the malaria inci-
dence was estimated at half of the low endemic rural areas
[11] (Table 1). In Botswana, Namibia, South Africa, Swa-
ziland, and Zimbabwe, the average incidence was esti-
mated at 0.03/py [10], with the age pattern distribution
similar to that of low endemic areas [6]. The proportion
of urban dwellers was assumed not to vary by malaria
endemicity. Urban and rural populations were based on
countries' definitions, with no standardization between
countries [12].
Geometric mean parasite density in falciparum malaria
patients was usually between 5,000 and 50,000/μl, with
the lowest densities found where transmission was low
and the highest where transmission was high [13]. In low
endemic and in high endemic urban areas, the mean par-
asite density in clinical cases was assumed to be 30,000/μl
in children <5 years old, 25,000/μl in those aged 5–14
years and 20,000/μl in patients aged ≥ 15 years. In high
endemic rural areas, the mean parasite density in clinical
cases was assumed to be 30,000/μl for children <5 years
old,, 20,000/μl for those aged 5–14 years, and 15,000/μl
for patients aged ≥ 15 years (Table 1). To allow the calcu-
lation of the population-level parasite biomass, the geo-
metric mean parasite densities were converted into
arithmetic means, by assuming that parasite densities in
symptomatic malaria have an exponential distribution
[14]. Arithmetic mean densities were therefore estimated
at 51,347/μl for children <5 years old, 42,789/μl for those
aged 5–14 years, and 34,231/μl for patients aged ≥ 15
years in low endemic and high endemic urban areas; in
high endemic rural areas the corresponding figures by age
group were 51,347/μl, 34,231/μl and 25,678/μl.Page 2 of 13
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towards severe disease [15], generally with higher parasite
densities than uncomplicated episodes. However, the
sequestration of P. falciparum-infected erythrocytes in the
deep circulation confounds the relationship between
peripheral parasite density and disease severity [16-19]. It
was assumed that 4% of clinical episodes both in low
transmission (all age groups) and high (children) trans-
mission areas evolve towards high parasite densities
(some of them would have severe malaria). In high-trans-
mission areas, 1.5% of all adult malaria episodes were
assumed to be hyperparasitaemic at enrolment. Based on
a recent model[20], these patients were assumed to have a
geometric mean parasite density of 458,000 parasites/μL
(309,659–678,910), corresponding to an arithmetic
mean of 784,000 parasites/μL (530,000–1,162,000).
Average blood volumes were estimated for each age group
on the basis of heights and weights, i.e. one liter in the <5
years old, two liters for the 5–14 years old and five liters
for the ≥ 15 years old (range across human populations
0.25–8 liters).
Malaria incidence and parasite density with HIV-1 
infection
The best evidence for an association between HIV infec-
tion and incidence of symptomatic malaria comes from
four longitudinal population-based studies in rural
Uganda and Malawi, where malaria is highly endemic. In
Uganda, odds ratios of symptomatic malaria in HIV-
infected compared to uninfected adults were 6.0, 3.4 and
1.2 for CD4 counts <200/μl, 200–499/μl and ≥ 500/μl,
respectively [1]. In another study in Uganda, the incidence
of symptomatic malaria in HIV-infected individuals var-
ied according to CD4 count and was 0.14/py, 0.093/py
and 0.057/py for CD4 count of <200/μL, 200–499/μL and
>500/μL, respectively (0.09/py, 0.053/py, and 0.022/py
when considering only episodes with more than 2,800
parasites/μL)[21]. In Malawi, incidence rates of sympto-
matic malaria in HIV-1 infected adults varied with CD4
count; compared to individuals with CD4 count of ≥ 500,
the malaria incidence was 3-fold higher with a CD4 count
of 200–499/μL and a 4.4-fold higher with a CD4 count
<200/μL [22]. Another study from Malawi reports malaria
incidence of 3.2/py, 4.9/py and 5.4/py in HIV-1 infected
adults with CD4 count of ≥ 400/μL, 200–399/μL and
<200/μL, respectively [23]. In most of these studies
malaria infection was not assessed at the time that CD4
count was done. This is a limitation as malaria itself
causes a temporarily and reversible decrease in peripheral
CD4 count (by one third) [24]. Therefore, the risk for clin-
ical malaria may increase at a higher-than-expected CD4
count. We assumed that, compared to HIV-1 negative
individuals, the risk of clinical malaria in HIV-1 infected
individuals with a CD4 count <200/μl and 200–499/μL is
5 and 3-fold higher, regardless of endemicity and age.
HIV-1 infected with a CD4 count ≥ 500 were expected to
have no additional risk.
HIV-1 infection considerably increases the risk of severe
malaria in adults [16,25,26]. In South Africa, in an area of
low (unstable) transmission, malaria-attributable mortal-
ity was nearly 7-fold higher in HIV-infected malaria
Table 1: Assumptions on malaria incidence rates, parasite density, and effects of HIV-1, sub-Saharan Africa*
Age group
HIV-negative persons and HIV-infected persons with CD4 ≥ 500/μl <5 years 5–14 years ≥ 15 years
Incidence of symptomatic malaria (per person-year) low/high endemicity[10]
Rural 0.18/1.4 0.18/0.59 0.09/0.11
Urban 0.09/0.18 0.091/0.18 0.046/0.09
Proportion of symptomatic episodes with hyperparasitaemia (includes severe malaria): 
low endemic and high endemic urban areas/high endemic rural areas
4.0%/4.0% 4.0%/1.5% 4.0%/1.5%
Geometric mean parasite density (/μL) in uncomplicated malaria: low endemic and high 
endemic urban areas/high endemic rural areas [13]
30,000/30,000 25,000/20,000 20,000/
15,000
Geometric mean parasite density (/μL) in severe malaria (all age groups and 
endemicities) [20]
458 000
Proportion of HIV-1 patients [6] with CD4<200/μl CD4 200–499/μL
Stabilized HIV epidemic 37% 25%
Rising HIV epidemic (e.g.Madagascar) 22% 15%
Relative change in HIV infection with CD4<200/μl CD4 200–499/μL
Relative risk of symptomatic malaria incidence (all age groups and endemicities) [1,21-
24]
5.0 3.0
Relative parasite density in symptomatic malaria 
(all age groups and endemicities) (Table 2)
3.0 1.5
Relative risk of progression to severe malaria (all age groups and endemicities) 
[16,25,26]
15.0 6
Relative parasite density during severe malaria (all age groups and endemicities) 1.0 1.0Page 3 of 13
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ongoing study in a meso-endemic region of Zambia, with
the highest risk in HIV-1 infected with low CD4 count
(Chalwe, unpublished data). We assumed that, compared
to HIV-1 negative individuals, the risk of severe malaria in
HIV-1 infected individuals with a CD4 count <200/μl and
200–499/μL is 15 and 6-fold higher, regardless of ende-
micity and age. HIV-1 infected with a CD4 count ≥ 500
were expected to have no additional risk.
Parasite density in clinical malaria and HIV-1 infection
HIV-1 infection tends to increase the mean parasite den-
sity, although this effect is largely limited to patients with
advanced immune suppression (Table 2). In HIV-1
infected individuals, the geometric mean parasite density
in uncomplicated malaria was assumed to be three-fold
higher at CD4 count <200/μl and 50% higher at CD4
count 200–499/μL, irrespective of malaria endemicity and
patient's age. For severe malaria, because parasite density
is already high and few data are available, it was conserv-
atively assumed that parasite density does not vary accord-
ing to HIV infection.
HIV-1 prevalence and CD4 counts in HIV-infected 
individuals
Point estimates of national HIV-1 prevalence for 2005 are
available from the Joint United Nations Programme on
HIV/AIDS (UNAIDS) [27]. The impact of HIV infection
was evaluated separately for urban and rural areas,
because of varying intensity of malaria transmission. The
urban-to-rural ratios in HIV-1 prevalence were estimated
from national household surveys or antenatal clinic sur-
veillance data [27,28]. For all countries, except Madagas-
car, it was assumed that 37% and 25% of HIV-infected
people have a CD4 count <200/μL and 200–499/μL
respectively, a good approximation for the African popu-
lations where HIV prevalence has stabilized [6]. For Mada-
gascar, where adult HIV prevalence is low but rising, 37%
of HIV-infected people were assumed to have a CD4 count
<500 μL [6].
HIV-1 infection and parasite biomass increase at 
population level
Annual parasite biomass was defined as the incidence rate
(per person-year) of symptomatic (uncomplicated and
severe) episodes multiplied by the total number of para-
sites circulating in the patient's peripheral blood at the
time of the clinical episode (i.e. when parasite density is
measured at a health facility). The parasite biomass was
estimated for each country by age group (<5, 5–15 and
above 15 years), by urban/rural and by low and high
endemicity taking into account the HIV-1 prevalence, the
incidence rates of uncomplicated and severe (hyperparasi-
taemic) malaria and their corresponding parasite density.
The overall country parasite biomass was computed by
summing up the estimations for each category listed
above.
To assess the sensitivity of the results, both univariate and
multivariate sensitivity analyses were performed. In the
univariate sensitivity analysis, the impact of HIV was
recalculated for two alternative scenarios, corresponding
to the lower and upper bound of the likely range. In the
multivariate sensitivity analysis, 95% confidence intervals
were calculated using the Monte Carlo simulation in
which 1,000 samples were taken from triangular distribu-
tions for all parameters [29] and the resulting propor-
tional increase in parasite was calculated. All statistical
analyses were performed using Microsoft Excel and the
statistical software R version 2.2.1 [30].
Results
In sub-Saharan Africa (41 countries), the HIV-1 epidemic
increases the malaria parasite biomass on average by
18.0% (95%CI: 11.6–26.9), ranging from 2.0% in Mada-
gascar to 243.9% in Swaziland. The highest proportional
increases were found in Southern African countries, where
HIV prevalence is the highest and malaria transmission
unstable (Table 3, Figure 1).
In absolute terms, HIV-1 infection increased the annual
malaria parasite biomass from 4.08*1019 (95%CI:
1.30–8.65*1019) to 4.86*1019
(95%CI:1.48–10.63*1019). Within the countries, the
median increase per person living in a malaria endemic
area was 7.5*109, ranging from 0.4*109 in Somalia to
54.3*109 in Mozambique (Table 3). The highest absolute
increases were found in countries where both HIV preva-
lence and malaria endemicity were high (Table 3, Figure
2), i.e. Zambia, Malawi, Mozambique and the Central
African Republic.
The sensitivity analysis (Table 4) shows that these esti-
mates are sensitive to the magnitude of the impact of HIV-
1 infection on the malaria incidence rates and associated
parasite densities, with the assumptions for uncompli-
cated episodes being more influential than those for
severe episodes. Excluding the effect of HIV-1 in children
did not markedly reduce the estimate of biomass increase
because in this age group the HIV-1 prevalence is low. For
all alternative scenarios, the country ranking of absolute
or relative increases in parasite biomass remained
unchanged (not shown). Combining the uncertainty
ranges on assumptions for all parameters presented in
Table 1, the overall 95%CI for the estimated relative
increase in parasite biomass would be 11.6–26.9% (best
estimate 18.0%).Page 4 of 13
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Table 2: Overview of African studies on geometric mean parasite densities during uncomplicated symptomatic malaria, by HIV-1 
status of the patient
Study Setting Median age
(range)
# patients (or 
malaria episodes,
 if indicated)
Parasite density, 
HIV-positive vs. HIV negative 
patients
Parasite density in HIV-infected:
 immune-suppressed vs. not immune-
suppressed*
CHILDREN HIGH 
ENDEMICITY
Values % change P-value Values % change P-value
Shaffer [45] Zaire, 1988 3.3 y 166 (6 HIV+) 93 325 vs 8 913/
μL
947% 0.04 ---
Mermin, 2004 [46] Uganda, 2001–3 0–5 y NR 154 vs 61/200 
WBC
152% 0.03 ---
Kamya, 2006 [47] Uganda, 2002–4 3 y 1802 28 186 vs 20 
076/μL 40% NS ---
Otieno, 2006 [19] Kenya, 2003–4 11 m 317 48 356 vs 47 
245/μL
2% NS ---
Greenberg, 2001 
[17]
DRC, 1986–8 5–21 m 271 episodes 4 173 vs 3 854/
μL
8% NS AIDS vs. HIV 
positive: 11256 vs 
2394/μL
370% 0.068
Taha, 1994 [48] Malawi, 1989 0–18 m 564 episodes --- NS ---
Colebunders, 1990 
[49]
Zaire, 1986–7 7 y 59 3 210 vs 4 170/
μL
-23% NS ---
Muller, 1990 [50] Uganda, 1989 11 m 75 --- NS ---
ADULTS HIGH 
ENDEMICITY
Mermin, 2004 [46] Uganda, 2001–3 34 y 90 episodes --- NS <200 vs. ≥ 200 
CD4/μL: 60 vs. 24/
200 WBC
185% 0.02
French [21] Uganda, 1995–98 31 y 153 episodes --- Association low 
CD4 ↔ high 
parasite density
0.0001
Kamya, 2006 [47] Uganda, 2002–4 28 y 163 20 537 vs 15 
174/μL
35% NS ---
Laufer, 2006 [22] Malawi, 2002–3 31.7 y 203 --- Association low 
CD4 ↔ high 
parasite density
0.005
Van geertruyden, 
2006 [37]
Zambia, 2003–5 27 y (15–50) 971 8 715 vs 8 538/μL 2% NS <300 vs. ≥ 300 CD4/μL: 10 093 
vs. 7328/μL
37% 0.03
Shah, 2006 [38] Kenya, 2002–4 Adults 619 11 732 vs 9 516/
μL
22% NS <200 vs ≥ 
200CD4/μL: 22 
515 vs. 8232/μL
173%, <0.005
Francesconi, 2001 
[18]
Uganda, 2000 25 y 170 --- NS ---
Whitworth, 2000 
[1]
Uganda, 1990–98 35 y 559 episodes --- NS Association low 
CD4 ↔ high 
parasite density
0.02
Simooya [51] Zambia, 1988 >12 y 170 --- 0.10 ---
Muller, 1990 [50] Uganda, 1989 26 y 200 --- NS ---
CHILDREN LOW 
ENDEMICITY
Kalyesubula, 1997 
[18]
Uganda, 1988 0–4 y 635 episodes --- NS ---
Grimwade, 2003 
[52]
South Africa, 
2000
7 y 663 --- NS ---
ADULTS LOW 
ENDEMICITY
Atzori, 1993 [2] Tanzania, 1991 18–41 y 300 --- NS ---
Grimwade, 2004 
[16]
South Africa, 
2000
30 y 613 16.7% vs 12.5%* 34% 036 ---
Birku, 2002 [36] Ethiopia, 2000 31 y 19 27 486 vs 32 
892/μL -16% NS ---
Abbreviations: NS = non-significant; --- = Not reported; m = months; y = years; RR = relative risk; WBC = white blood cells. *All studies except for [23] measured CD4 
count during malaria episodes, which, due to the temporary decrease in CD4 caused by symptomatic malaria [24], probably inflated the CD4 threshold below which HIV-
related immune-suppression starts to increase malaria incidence.
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Impact of HIV on parasite biomass
The HIV-1 epidemic may have increased malaria parasite
biomass in sub-Saharan Africa by 17.4%. The highest
absolute increases were found in countries with both high
malaria and HIV burden (Zambia, Malawi, Mozambique
and the Central African Republic). A recently published
model [7] found that the largest epidemiological impact
occurs when one baseline measure is very high while the
other is very low and near its endemic threshold. When
both prevalences were very high, the direct epidemiologi-
cal impact of the interaction seemed to be minimal. It is
indeed conceivable that, when both diseases reach an epi-
demic equilibrium, the epidemiological impact of the
interaction will be minimal while the disease interaction
should be maximal. Nevertheless, when both diseases are
at epidemic equilibrium, there may be an indirect but
important epidemiological impact such as the increased
parasite biomass, higher biodiversity and higher probabil-
ity of de novo resistance mutations emerging.
The model presented has several limitations. Pregnant
women were not considered in the model as the parasite
biomass in this high-risk group and its changes according
to the HIV-1 infection could not be estimated, partly
because of the sequestration of parasites in the placenta.
Considering that pregnant women are particularly vulner-
able to malaria infection and that such vulnerability is
increased by HIV-1 infection, their exclusion may have led
to an underestimation of the actual impact of HIV-1 infec-
tion at population level.
Moreover, the possible impact of HIV-1 infection on par-
asite density in asymptomatic individuals was not consid-
ered. This simplification may be justified because, due to
the logarithmic distribution of malaria parasites in
human populations, asymptomatic carriers, despite out-
numbering the clinical cases, carry only a small propor-
tion (probably less then 1/1000) of the world's
potentially transmissible parasites [31,32]. In addition,
asymptomatic infections most often are not treated,
reducing the risk of selecting resistant parasites. In
absence of drug pressure, mutant resistant parasites may
be "less fit" and possibly less transmitted. However, once
resistance has emerged and spread above a certain thresh-
old, asymptomatic infections could play a substantial role
for its further spread, especially in high endemic areas,
and this effect could be enhanced by a higher prevalence
of asymptomatic infection in HIV co-infected individuals.
The spread of these resistant strains should be calculated
by a stochastic model where asymptomatic carriers most
probably play an important role.
An additional limitation of the model presented is the
assumption that the effect of the HIV-1 infection on para-
site density is constant throughout the clinical episode.
This may not be true as the actual parasite density may
vary throughout the clinical episode.
Impact of HIV on the emergence of antimalarial drug 
resistance?
Several factors determine the probability of selecting the
de novo mutations linked to antimalarial drug resistance
[33]. Amongst them, the frequency at which the resistance
mutation occurs and the number of parasites in the
human host exposed to the drug are considered as inde-
pendent risk factors. If the probability of de novo resistance
mutations is distributed evenly among all parasites then
the biomass increment due to HIV-1 directly increases the
rate at which these mutations occur.
Mathematical models of malaria epidemiology and drug
resistance represent important tools in guiding malaria
control strategies. They consistently predict that once drug
resistance arises, it spreads rapidly, with the level of host
immunity (both aspecific and specific) considered as an
additional important independent factor. Although the
dynamics underlying the spreads of antimalarial resist-
ance may be much more complex than previously realized
[34], the cycle of the emergence and subsequent spread of
antimalarial drug resistance [35], and the influence of
HIV-1-related immune-suppression can be schematically
represented (Figure 3). Drug resistance starts with one or
several genetic mutations in parasites which, if exposed to
the drug, are selected and may spread. HIV-1 infection
contributes to the emergence and spread of drug resist-
ance by increasing drug exposure and drug pressure. HIV-
1 infection increases the probability of a malaria infection
progressing to symptomatic illness and to a higher para-
site densities, increasing the probabilities of treatment
and contact between the parasites and the drug [1,21-23].
In addition, immune suppressed HIV-infected adults suf-
fer frequently of non-malaria-attributable acute fevers that
may be misdiagnosed as malaria and treated as such [22].
Once resistance has emerged and spread above a certain
threshold, malaria treatment of non-malaria fever in HIV
immune-suppressed individuals might contribute to the
further spread of drug resistance by increasing the drug
pressure on asymptomatic malaria infections. After treat-
ment, a delayed cure rate [36] and a higher rate of recru-
descence [37,38], a phenomenon already described in
HIV-1 infected individuals, accelerate the spread of resist-
ant parasites and increase the parasite biomass in sympto-
matic patients and asymptomatic carriers alike.
Besides contributing to the emergence and spread of anti-
malarial drug resistance, HIV-1 infection may influence
and modify its expected geographical pattern. It has been
postulated that antimalarial drug resistance first emerges
and spreads in low-endemic areas, where the populationPage 6 of 13
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Table 3: Estimated impact of HIV on malaria parasite biomass, sub-Saharan Africa, 2005*
Country Adult HIV prevalence Urban† % low-high
malaria endemic
Parasite biomass*109
/individual at risk in the
absence of HIV‡
HIV-related additional
parasite biomass*109
/individual at risk‡
Proportional increase in
parasite load due to 
HIV
(95%CI)
Mozambique 16.1% 38% 4 – 96 77.2 54.3 64.0 (41.0–95.8)
Zambia 17% 36.5% 16 – 83 67.8 42.8 59.1 (35.3–94.3)
Malawi 14.1% 17.2% 22 – 77 75.3 40.2 54.1 (26.4–96.8)
CARepublic 10.7% 43.8% 0 – 10 76.6 32.2 41.9 (23.4–77.3)
Uganda 6.5% 12.4% 20 – 73 75.3 20.6 25.2 (14.4–37.0)
Togo 6.7% 36.3% 0 – 100 82.2 19.1 22.1 (13.2–35.1)
Cote d'Ivoire 7.1% 45.8% 0 – 100 75.9 19.1 23.4 (14.2–39.1)
Congo 5.3% 54.4% 0 – 100 62.5 13.2 18.6 (9.8–29.3)
Swaziland 33.4% 23.9% 69 – 0 5.6 12.8 243.9 (122.1–402.3)
Gabon 7.9% 85.2% 0 – 96 38.5 12.5 30.7 (19.6–53.0)
Nigeria 3.9% 48.3% 1 – 99 70.8 12.0 16.7 (9.4–26.6)
Guinea-Bissau 3.8% 35.6% 0 – 100 78.9 11.4 13.9 (7.9–23.6)
Cameroon 5.4% 52.9% 24 – 74 53.3 11.3 20.1 (13.3–31.2)
Chad 3.5% 25.8% 14 – 86 76.3 11,2 15.1 (6.4–23.9)
Gambia 2.4% 26.1% 0 – 100 95.4 10.8 11.3 (5.8–19.0)
Botswana 24.1% 52.5% 13 – 0 4.9 9.3 197.6 (116.5–278.9)
DRCongo 3.2% 32.7% 10 – 85 73.7 9.2 12.2 (6.5–20.4)
Liberia 4% 47.9% 0 – 100 69.2 9.1 12.2 (7.3–21.5)
Equat Guinea 3.2% 50% 02–97 68.1 8.4 11.7 (7.1–18.0)
Tanzania 3.2% 37.5% 21 – 75 65.0 7.8 11.2 (5.8–19.4)
Zimbabwe 20.1% 35.9% 54 – 0 5.2 7.5 144.2 (75.6–221.0)
Ghana 2.3% 46.3% 02 – 98 76.1 7.5 9.2 (5.5–13.5)
Namibia 19.6% 33.5% 8 – 0 5.3 7.1 134.9 (74.4–247.1)
South Africa 18.8% 57.9% 15 – 0 5.0 6.8 137.0 (84.5–212.1)
Burkina Faso 2% 18.6% 0 – 100 94.9 6.5 6.8 (3.7–10.9)
Sudan 2.3% 40.8% 42 – 56 48.9 5.8 13.4 (4.2–28.3)
Kenya 6.1% 47.9% 57 – 21 22.8 5.7 25.6 (15.3–37.7)
Angola 3.7% 37.2% 53 – 46 38.9 5.7 14.7 (8.8–23.4)
Mali 1.7% 33.7% 10–90 72.7 5,0 6.5 (3.7–10.0)
Guinea 1.5% 36.5% 01–99 81.0 5.0 5.6 (3.3–8.3)
Benin 1.8% 46.1% 0 – 100 73.7 5.0 6.4 (3.6–10.4)
Burundi 3.3% 10.6% 64 – 21 29.9 4.1 13.5 (8.0–18.9)
Niger 1.1% 23.3% 11 – 89 79.4 2.8 3.5 (1.8–6.6)
Sierra Leone 1.6% 40.2% 0 – 100 78.9 2.7 3.6 (1.7–5.8)
Senegal 0.9% 51% 03–97 68.1 2.6 3.9 (2.1–6.4)
Eritrea 2.4% 20.8% 83 – 16 19.5 2.3 11.4 (5.8–19.8)
Ethiopia 2% 16.2% 50 – 14 25.7 2.0 8.2 (3.8–13.3)
Rwanda 3.1% 21.8% 60 – 7 14.3 2,0 13.8 (8.1–19.0)
Mauritania 0.7% 64.3% 59 – 41 25,4 1.3 5.3 (1.9–10.5)
Madagascar 0.5% 27% 36 – 60 58.3 1.1 2.0 (0.9–3.7)
Somalia 0.9% 35.9% 96 – 3 7.2 0.4 5.6 (2.5–9.2)
Average Africa$ 6.1% 23 – 87 55.1 9.9 18.0% (11.6–26.9)
Median Africa 3.5% 36.5% 11–83 68.0 7.5 14.1 (9.2–20.5)
*Excluded from analyses were the following small countries: Seychelles, Reunion and Comoros, which are at negligible malaria risk and the islands of 
Sao Tome & Principe and Cap Verde, which are subject to stable transmission but have not been precisely characterized in the malaria risk model. 
Calculations used country-specific age distributions, based on HIV-1 prevalence estimates by UNAIDS/World Health Organization (WHO) for end 
of 2005[27], and assuming urban/rural ratios in HIV prevalence estimated by UNAIDS/WHO) for end of 2003 [27,28]
† Urban and rural populations were based on countries' definitions[12], without standardization between countries.
‡ Individual at risk is person living in a malaria prone area.
$ Weighted according to countries' population size living in malaria endemic areas.
Malaria Journal 2008, 7:134 http://www.malariajournal.com/content/7/1/134acquired immunity is so low that most infections are
symptomatic and thus treated, exposing a large numbers
of parasites to antimalarial drugs [39]. In highly endemic
areas, less malaria infections become symptomatic and
are treated (especially in adults). In sub-Saharan Africa,
when considering the geographical distribution of both
Additional parasite biomass due to HIV-1 in individuals living in malaria riskFigure 1
Additional parasite biomass due to HIV-1 in individuals living in malaria risk. No Malaria Transmission 
. < 10% Parasite Biomass increase* . 10–99% Parasite Biomass increase* . ≥ 100% Para-
site Biomass increase* . *High Malaria Transmission areas shaded.Page 8 of 13
(page number not for citation purposes)
Malaria Journal 2008, 7:134 http://www.malariajournal.com/content/7/1/134the HIV-1 infection and the spread of drug resistance (to
chloroquine and sulphadoxine-pyrimethamine) [33,40],
the latter having been faster in eastern-southern (high
HIV-1 prevalence) than in western Africa (relatively low
HIV-1 prevalence) [41], the question on the role of HIV-1
pandemic as an additional contributing factor could be
Additional parasite biomass due to HIV-1 in individuals living in malaria risk areas in absolute terms *Figure 2
Additional parasite biomass due to HIV-1 in individuals living in malaria risk areas in absolute terms *. No 
Malaria Transmission . < 3 *109 parasites/individual at risk increase* . 3–20*109 parasites/individual at 
risk increase* . ≥ 20 *109 parasites/individual at risk increase* . *High Malaria Transmission areas 
shaded.Page 9 of 13
(page number not for citation purposes)
Malaria Journal 2008, 7:134 http://www.malariajournal.com/content/7/1/134raised. It is impossible to provide a definitive answer
though the results of the model presented in this paper are
compatible with an influence of HIV-1 infection on the
epidemiology of antimalarial drug resistance.
Malaria parasite biomass is influenced through various
malaria control interventions. Easy access, prompt diag-
nosis and efficacious treatment with combination therapy
are essential to halt or delay the emergence and spread of
antimalarial drug resistance [9]. The artemisinin deriva-
tives, commercialized in the last decade, are the most
potent antimalarial drugs with parasite reduction levels of
10,000 per cycle. Furthermore, if used in combination,
the artemisinin component is protected by the partner
drug and the parasite reduction rate is positively affected.
Unfortunately, it is still unclear how treatment combina-
tions for both malaria and HIV-1 interact. More data on
the biological effects of therapy combinations would be of
great utility to complement recent 'in vitro' evidence of a
synergistic effect between protease inhibitors and antima-
larials [32]. Preventive interventions are equally impor-
tant as they diminish the parasite load, transmission and
drug pressure. Indeed, the incidence of symptomatic
malaria in HIV-infected adults can decrease by 95% by
giving cotrimoxazole prophylaxis and antiretroviral treat-
ment combined with insecticide-treated bed nets [42].
Furthermore, next to individual protection, preventive
activities as indoor residual spraying, use of bed nets and
cotrimoxazole prophylaxis reduce the parasite biomass at
community level. For indoor residual spraying this is
quite obvious as it is a community intervention but it has
been shown that cotrimoxazole prophylaxis taken by
HIV-infected people was associated with decreased mor-
bidity and mortality among family members [43]. Recent
modeling has demonstrated that insecticide-treated nets
protection has a substantial impact on the circulating
Table 4: Sensitivity analyses on the estimated relative increase in Plasmodium falciparum parasite biomass due to HIV-1, sub Saharan 
Africa*
Relative increase parasite
 biomass
Best estimate (95% CI)* 18.0%(11.6–26.9)
Parameters Lower-bound assumption Upper-bound assumption Lower-bound assumption Upper-bound assumption
HIV prevalence 
(UNAIDS country point 
estimate)
lower-bound higher-bound 11.4% 23.8%
Relative risk of incidence of 
uncomplicated 
symptomatic malaria, in 
HIV-infected individuals 
with CD4<200/μl and CD4 
200–499 compared to HIV-
negatives
4/2 6/4 15.8% 19.4%
Relative parasite density 
during uncomplicated 
symptomatic malaria, in 
HIV-infected patients with 
CD4<200/μl and CD4 
200–499/μL compared to 
HIV-uninfected patients
2/1 4/2 15.5% 19.9%
Relative risk of progression 
to severe malaria, in HIV-
infected individuals with 
CD4<200/μl and CD4 
200–499/μL compared to 
HIV-uninfected patients
8/3 24/12 17.2% 18.6%
Relative parasite density 
during severe malaria, in 
HIV-infected patients with 
CD4<500/μl compared to 
HIV-uninfected patients
0.5/0.5 2.0/2.0 16.9% 18.2%
Assume no HIV-1 impact on incidence of symptomatic malaria, severe malaria or 
parasite density in children under 15 years
17.6% n.a.
Mean parasite density during uncomplicated symptomatic malaria in HIV-negative 
patients equal for all age groups and endemicities: 20000/μL
n.a. 17.2%
* For default values underlying this best estimate, see Table 2.Page 10 of 13
(page number not for citation purposes)
Malaria Journal 2008, 7:134 http://www.malariajournal.com/content/7/1/134malaria parasite biomass and has community-wide bene-
fits that are often underestimated [44]. Therefore, during
the ongoing scale-up of HIV/AIDS and malaria control
measures, HIV-1 infected individuals should be consid-
ered a priority group for the distribution of insecticide-
treated nets, co-trimoxazole prevention and artemisinin-
based combination therapy.
Conclusion
Earlier studies on the impact of HIV infection on malaria
morbidity and mortality focused on the direct effects in
HIV-infected people. They concluded that the population-
level effect was limited because of different geographical
distribution and contrasting age patterns of the two dis-
eases. However, the model presented suggests that the
overall impact of HIV-1 infection may be greater than pre-
viously estimated. If HIV-1 is a major contributing factor
for the emergence of antimalarial drug resistance, this will
have a major impact over the whole population by
increasing malaria morbidity and mortality. A second sto-
chastic model dealing with the contribution of HIV-1
infection on the spread of antimalarial drug resistance
once resistance has emerged is currently under develop-
ment.
Preventive interventions, easy access, prompt diagnosis
and efficacious treatment with combination therapy are
essential to diminish the parasite biomass, transmission
and drug pressure and halt or delay the emergence and
spread of antimalarial drug resistance [9]. This is even
more important for HIV-1 infected malaria patients. Tar-
geting this vulnerable group will greatly contribute to
malaria control and will benefit the whole population in
endemic countries.
Effects of HIV on the emergence and consequent spread of antimalarial drug resistance in human populationsFigure 3
Effects of HIV on the emergence and consequent spread of antimalarial drug resistance in human populations.Page 11 of 13
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